Home » USA Broker Ratings » DexCom – Consenus Indicates Potential 10.3% Upside

DexCom – Consenus Indicates Potential 10.3% Upside

DexCom found using ticker (DXCM) have now 16 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 330 and 240 calculating the average target price we see 290.06. With the stocks previous close at 262.96 this indicates there is a potential upside of 10.3%. The 50 day MA is 258.94 and the 200 day moving average is 212.63. The company has a market capitalisation of $25,463m. Company Website: http://www.dexcom.com

DexCom, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom was founded in 1999 and is headquartered in San Diego, California.

Join us on our new LinkedIn page

Follow us on LinkedIn